A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Titel:
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity
Auteur:
Tol, J. Koopman, M. Rodenburg, C.J. Cats, A. Creemers, G.J. Schrama, J.G. Erdkamp, F.L.G. Vos, A.H. Mol, L. Antonini, N.F. Punt, C.J.A.